Literature DB >> 9049580

The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.

P M Christensen1, P C Gøtzsche, K Brøsen.   

Abstract

OBJECTIVE: To examine the association between the sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer.
METHOD: Meta-analysis of case-control studies using a random effects model. The "Main outcome measure" was the odds ratio for the risk of lung cancer, using extensive metabolisers as the reference group.
RESULTS: Thirteen studies were identified. The studies were too heterogeneous to be pooled the size of the odds ratio increased with the sample size. When the analysis was restricted to the largest studies, there was no difference in risk between poor and extensive metabolisers (odds ratio 0.95, 95% confidence interval 0.68-1.33).
CONCLUSION: No association was found between the CYP2D6 oxidation polymorphism and lung cancer risk when sample size bias was taken into account.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9049580     DOI: 10.1007/s002280050219

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  36 in total

1.  Dextromethorphan oxidation phenotypes as markers for susceptibility to lung cancer.

Authors:  G B Faccini; V Puchetti; N Zatti
Journal:  Clin Chem       Date:  1990-02       Impact factor: 8.327

2.  Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification.

Authors:  M Heim; U A Meyer
Journal:  Lancet       Date:  1990-09-01       Impact factor: 79.321

3.  Is there a link between debrisoquine oxidation phenotype and lung cancer susceptibility?

Authors:  Y Horsmans; J P Desager; C Harvengt
Journal:  Biomed Pharmacother       Date:  1991       Impact factor: 6.529

4.  CYP2D6 genotype and lung cancer risk according to histologic type and tobacco exposure.

Authors:  I Stücker; J Cosme; P Laurent; S Cenée; P Beaune; J Bignon; A Depierre; B Milleron; D Hémon
Journal:  Carcinogenesis       Date:  1995-11       Impact factor: 4.944

5.  CYP2D6 genotyping and the association with lung cancer susceptibility.

Authors:  C R Wolf; C A Smith; T Bishop; D Forman; A C Gough; N K Spurr
Journal:  Pharmacogenetics       Date:  1994-04

6.  Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations.

Authors:  G Alván; P Bechtel; L Iselius; U Gundert-Remy
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

7.  Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6.

Authors:  B W Penman; J Reece; T Smith; C S Yang; H V Gelboin; F J Gonzalez; C L Crespi
Journal:  Pharmacogenetics       Date:  1993-02

8.  The effect of tobacco on lung cancer risk depends on CYP2D6 activity.

Authors:  C Bouchardy; S Benhamou; P Dayer
Journal:  Cancer Res       Date:  1996-01-15       Impact factor: 12.701

9.  Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo.

Authors:  S Kato; E D Bowman; A M Harrington; B Blomeke; P G Shields
Journal:  J Natl Cancer Inst       Date:  1995-06-21       Impact factor: 13.506

10.  Lung cancer and the debrisoquine metabolic phenotype.

Authors:  N E Caporaso; M A Tucker; R N Hoover; R B Hayes; L W Pickle; H J Issaq; G M Muschik; L Green-Gallo; D Buivys; S Aisner
Journal:  J Natl Cancer Inst       Date:  1990-08-01       Impact factor: 13.506

View more
  8 in total

Review 1.  Contributions of human enzymes in carcinogen metabolism.

Authors:  Slobodan Rendic; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2012-05-10       Impact factor: 3.739

Review 2.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

3.  CYP2D6 T188C variant is associated with lung cancer risk in the Chinese population.

Authors:  Yan Huang; Xin Liu; Xin Kuang; Duanfang Liao
Journal:  Tumour Biol       Date:  2013-04-05

4.  Genetic polymorphisms of phase I and phase II metabolic enzymes as modulators of lung cancer susceptibility.

Authors:  P Mota; H C Silva; M J Soares; A Pego; M Loureiro; C Robalo Cordeiro; F J Regateiro
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-12       Impact factor: 4.553

Review 5.  Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.

Authors:  Ulrich M Zanger; Sebastian Raimundo; Michel Eichelbaum
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-15       Impact factor: 3.000

Review 6.  Impact of genetic notification on smoking cessation: systematic review and pooled-analysis.

Authors:  Sylviane de Viron; Johan Van der Heyden; Elena Ambrosino; Marc Arbyn; Angela Brand; Herman Van Oyen
Journal:  PLoS One       Date:  2012-07-11       Impact factor: 3.240

7.  LncRNAs are altered in lung squamous cell carcinoma and lung adenocarcinoma.

Authors:  Bing Liu; Yifei Chen; Jiong Yang
Journal:  Oncotarget       Date:  2017-04-11

8.  Untangling SNP Variations within CYP2D6 Gene in Croatian Roma.

Authors:  Anita Stojanović Marković; Matea Zajc Petranović; Željka Tomas; Borna Puljko; Maja Šetinc; Tatjana Škarić-Jurić; Marijana Peričić Salihović
Journal:  J Pers Med       Date:  2022-02-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.